March 12, 2020 · Phase 3 readout
AMGN Phase 3 readout: a negative outcome, -8.3%
-8.3%Amgen Inc. (AMGN) →
On March 12, 2020, Blinatumomab — Amgen Inc. (Acute Lymphoblastic Leukemia) reached its Phase 3 readout. The result was a negative outcome, and the stock moved -8.3% in the window around the event. It had already run -13.4% in the 30 days into the catalyst — the kind of pre-event run-up that often precedes binary readouts.
The move
$198.65
1d before
$182.24
Event day
$202.10
1d after
$207.80
5d after
Pre-catalyst setup
-13.4%
30-day run-up
7288%
30-day volatility